Home >Companies >News >Glenmark Pharmaceuticals launches COVID-19 drug after DCGI nod
Glenmark’s India business grew by 7.61% to ₹663.29 crore, while in the US it declined by 32.66% to ₹703.74 crore.
Glenmark’s India business grew by 7.61% to ₹663.29 crore, while in the US it declined by 32.66% to ₹703.74 crore.

Glenmark Pharmaceuticals launches COVID-19 drug after DCGI nod

FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement

Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.

The Mumbai-based drug firm had on Friday received manufacturing and marketing approval from the Drugs Controller General of India (DCGI).

FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.

"This approval comes at a time when cases in India are spiralling like never before, putting a tremendous pressure on our healthcare system," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.

The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option, he added. PTI MSS ABM ABM

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
x
×
My Reads Redeem a Gift Card Logout